Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Emerging issues related to COVID-19 vaccination in patients with cancer

Emerging issues related to COVID-19 vaccination in patients with cancer Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Emerging issues related to COVID-19 vaccination in patients with cancer

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/emerging-issues-related-to-covid-19-vaccination-in-patients-with-wbqBdJ4bB0
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00157-1
Publisher site
See Article on Publisher Site

Abstract

Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2021

Keywords: Cancer; COVID-19; Efficacy; mRNA; SARS-CoV-2; Toxicity; Vaccine; Viral vector

References

  • The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
    Osuchowski, MF; Winkler, MS; Skirecki, T
  • Effect of the COVID-19 pandemic on cancer treatment and research
    Saini, KS; de Las, HB; de Castro, J
  • Reimagining global oncology clinical trials for the postpandemic era: a call to arms
    Saini, KS; de Las, HB; Plummer, R
  • Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation’s young oncologists
    Meattini, I; Franco, P; Belgioia, L
  • Cancer care during the spread of coronavirus disease (COVID-19) in Italy: young oncologists’ perspective
    Lambertini, M; Toss, A; Passaro, A
  • Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months
    de Las, HB; Saini, KS; Boyle, F
  • SARS-CoV-2 vaccines for cancer patients: a call to action
    Corti, C; Crimini, E; Tarantino, P
  • Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
    Saini, KS; Lanza, C; Romano, M
  • Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19
    Wang, X; Sahu, KK; Cerny, J
  • Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies
    Saini, KS; Tagliamento, M; Lambertini, M
  • Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis
    Tagliamento, M; Agostinetto, E; Bruzzone, M
  • Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis
    Zhang, H; Han, H; He, T
  • Challenges of cellular therapy during the COVID-19 pandemic
    Sahu, KK; Ailawadhi, S; Malvik, N; Cerny, J
  • A rationale to prioritise vaccination of HSCT patients against COVID-19
    Leclerc, M; Maury, S
  • Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
    Ribas, A; Sengupta, R; Locke, T
  • SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
    Poland, GA; Ovsyannikova, IG; Kennedy, RB
  • Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. Locations, December 2020-March 2021
    Thompson, MG; Burgess, JL; Naleway, AL
  • SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
    Kyriakidis, NC; López-Cortés, A; González, EV; Grimaldos, AB; Prado, EO
  • The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: vaccinate monitor educate
    Garassino, MC; Vyas, M; de Vries, EGE
  • COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
    Hwang, JK; Zhang, T; Wang, AZ; Li, Z
  • Attitudes of patients with cancer towards vaccinations-results of online survey with special focus on the vaccination against COVID-19
    Brodziak, A; Sigorski, D; Osmola, M
  • Cancer and COVID-19 vaccines: a complex global picture
    Yusuf, A; Sarfati, D; Booth, CM
  • Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak
    Tagliamento, M; Spagnolo, F; Poggio, F
  • Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
    Saini, KS; Punie, K; Twelves, C
  • Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
    Keech, C; Albert, G; Cho, I
  • Adjuvantation helps to optimise COVID-19 vaccine candidate
    Li, J-X; Zhu, F-C
  • Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
    Waissengrin, B; Agbarya, A; Safadi, E; Padova, H; Wolf, I
  • Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
    Monin, L; Laing, AG; Muñoz-Ruiz, M
  • US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26COV2S vaccination , March 2 to April 21, 2021
    See, I; Su, JR; Lale, A
  • Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC subcommittee on platelet immunology
    Nazy, I; Sachs, UJ; Arnold, DM
  • SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia
    Cines, DB; Bussel, JB
  • Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH
    Oldenburg, J; Klamroth, R; Langer, F
  • Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
    Schultz, NH; Sørvoll, IH; Michelsen, AE
  • Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
    Østergaard, SD; Schmidt, M; Horváth-Puhó, E; Thomsen, RW; Sørensen, HT
  • Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
    Pottegård, A; Lund, LC; Karlstad, Ø
  • Supportive care in patients with cancer during the COVID-19 pandemic
    Aapro, M; Lyman, GH; Bokemeyer, C
  • Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
    Lee, E-J; Cines, DB; Gernsheimer, T
  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
    Voysey, M; Costa Clemens, SA; Madhi, SA
  • Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
    Palich, R; Veyri, M; Marot, S
  • Interplay between emerging SARS-CoV-2 variants and pandemic control
    Neuzil, KM
  • Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
    Madhi, SA; Baillie, V; Cutland, CL
  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
    Emary, KRW; Golubchik, T; Aley, PK
  • Effectiveness of the BNT162b2 Covid-19 Vaccine against the B117 and B1351 Variants
  • Persistence and evolution of SARS-CoV-2 in an immunocompromised host
    Choi, B; Choudhary, MC; Regan, J
  • SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity
    Siqueira, JD; Goes, LR; Alves, BM
  • Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
    Shaw, RH; Stuart, A; Greenland, M; Liu, X; Van-Tam, JSN; Snape, MD
  • Mix-and-match COVID vaccines trigger potent immune response
    Callaway, E
  • COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
    Desai, A; Gainor, JF; Hegde, A
  • COVID-19 vaccines in patients with cancer-a welcome addition, but there is need for optimization
    Korompoki, E; Gavriatopoulou, M; Kontoyiannis, DP
  • COVID-19 vaccination-related lymphadenopathy: what to be aware
    Tu, W; Gierada, DS; Joe, BN
  • Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: a pragmatic approach
    Lehman, CD; Lamb, LR; D’Alessandro, HA
  • COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic
    Lee, AJX; Purshouse, K